Oncology News

Patients with hepatocellular carcinoma on hemodialysis for end-stage renal disease had a higher mortality rate than non-dialyzed patients when treated with radiofrequency ablation, according to a recently published study.

BTG received Class III CE Mark certification for its DC Bead LUMI, a radiopaque drug-eluting bead for patients with hepatocellular carcinoma and malignant colorectal cancer metastasized to the liver, according to a press release.

Treating patients with hepatitis C and hepatocellular carcinoma or decompensated cirrhosis with all-oral direct-acting antiviral therapy prior to liver transplantation had highly effective results and was more cost effective than treating post-LT, according to simulated results of a recent study.

Direct-acting antiviral treatment cured HCV in most patients with prior hepatocellular carcinoma and in almost all patients who received a liver transplant as treatment for HCC, according to a recently published study.

NeuroVive announced two research agreements designed to further develop the company’s new drug compounds in the pipeline for the treatment of nonalcoholic steatohepatitis and hepatocellular carcinoma, according to a press release.

Sorafenib improved OS among patients with hepatocellular carcinoma who were hepatitis C positive but hepatitis B negative, suggesting that the beneficial effects of sorafenib may be based on hepatitis status, according to results of a meta-analysis.

A phase 3 study of tivantinib as second-line treatment for hepatocellular carcinoma failed to meet its primary endpoint of improved OS, according to the drug’s manufacturers.

Theodore H. Welling, III, MD, has been named director of a new liver tumor program at NYU Langone’s Perlmutter Cancer Center.

Gold standard monitoring for hepatocellular carcinoma in patients with cirrhosis, as recommended by guidelines, was more cost-effective and beneficial to patients compared with real-life monitoring, according to the results of a simulation study.

Risks for hepatocellular carcinoma and non-Hodgkin lymphoma appeared greater among women who had undergone a blood transfusion more than 5 years earlier, according to results of a prospective study conducted in the United Kingdom.